Vestal Point Capital, LP Allogene Therapeutics, Inc. Transaction History
Vestal Point Capital, LP
- $1.69 Trillion
- Q4 2024
A detailed history of Vestal Point Capital, LP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 1,500,000 shares of ALLO stock, worth $2.43 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
1,500,000
Previous 1,500,000
-0.0%
Holding current value
$2.43 Million
Previous $4.2 Billion
23.93%
% of portfolio
0.19%
Previous 0.32%
Shares
3 transactions
Others Institutions Holding ALLO
# of Institutions
177Shares Held
139MCall Options Held
75.8KPut Options Held
52.8K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$30.3 Million1.1% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$26.6 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR10.9MShares$17.6 Million9.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8MShares$13 Million0.0% of portfolio
-
State Street Corp Boston, MA7.25MShares$11.7 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $233M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...